Roivant Sciences Ltd (FRA:87S)
€ 11.525 0.15 (1.32%) Market Cap: 8.62 Bil Enterprise Value: 3.56 Bil PE Ratio: 2.21 PB Ratio: 1.78 GF Score: 60/100

Roivant Sciences Ltd at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 02:00PM GMT
Release Date Price: €8.75 (+4.17%)
Dennis Ding
Jefferies - Analyst

Good morning. Welcome, everybody, to the 2023 Jefferies Healthcare Conference. My name is Dennis Ding, biotech analyst here at Jefferies. And I have the great pleasure of having Roivant here with us for a fireside, and we have CEO Matt Gline here.

Questions & Answers

Dennis Ding
Jefferies - Analyst

Matt, I mean, there's obviously been a ton of interest around the company, around the pipeline. You guys had some really interesting and promising data, particularly around TL1A, which is only one aspect of the story.

So maybe, before we start off, just level-set us. Talk about some of the Phase 2 data you guys had in January, the induction data in ulcerative colitis, and the path forward and some of the next steps for that program.

Matt Gline
Roivant Sciences Ltd. - CEO

Yeah. Perfect. Thank you. Thank you, Dennis. Thanks for having us. We're obviously really happy to be here. It's nice to have a conference so close to home; our office is just across the street.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot